DXS International (STU:7EE) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:7EE DXS International PLC STU:7EE
39 GF Score
Price €0.01
GF Value €0.02
! 2 Warning Signs
View Full Analysis

What is DXS International FFO per Share?

FFO per Share only applies to REITs.

STU:7EE
39GF Score
DXS International PLC STU:7EE
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is DXS International (STU:7EE) Overvalued in 2026?

Based on GuruFocus' analysis, DXS International stock appears to be undervalued. The current stock price of €0.01 is trading 45% below its estimated GF Value™ of €0.02.

Key valuation signals for STU:7EE:

  • FFO per Share:
  • GF Value™: €0.02 vs. price of €0.01 (45% below fair value)
  • GF Score™: 39/100 with 2 warning signs

No single metric tells the full story. See the STU:7EE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


DXS International Business Description

Other Exchanges DXSP:UK
Address 119 Saint Mary’s Road, Market Harborough, London, Leicestershire, GBR, LE16 7DT
DXS International PLC is engaged in the development and distribution of clinical decision support systems for General Practitioners, nurses, and retail pharmacies in the United Kingdom and South Africa. Its commercial activities include licensing DXS products to various ICBs, offering e-detailing opportunities to the pharmaceutical industry and the UK primary care sector, and licensing its technology to healthcare publishers. The company's products include BestPathway and Point-of-Care ExpertCare.
39GF Score

Get the complete analysis for STU:7EE

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.01
Price
€0.02
GF Value